Patents by Inventor Timothy Piser

Timothy Piser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20250034145
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 29, 2024
    Publication date: January 30, 2025
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240199617
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: July 13, 2023
    Publication date: June 20, 2024
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 11542264
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: January 3, 2023
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210403474
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 12, 2021
    Publication date: December 30, 2021
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10752633
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: August 25, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200131190
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 30, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10584131
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 10, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200039987
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Nicotinic Acetylcholine Receptor Ligands 101
    Publication number: 20110136804
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Application
    Filed: November 5, 2010
    Publication date: June 9, 2011
    Applicant: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Nicotinic acetylcholine receptor ligands 101
    Patent number: 7842803
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: November 30, 2010
    Assignee: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Composition Comprising (R)-Spiro[L-Azabicyclo[2.2.2]Octane-3,2'(3'H)-Furo[2,3-B]Pyridine (AZD0328) and its Use in the Treatment of Alzheimer's Disease, ADHD or Cognitive Dysfunction
    Publication number: 20100168146
    Abstract: A pharmaceutical composition comprising (R)-spiro[1-azabicyclo[2.2.2]octane-3,2?(3?H)-furo[2,3-b]pyridine (AZD0328) and its use in the treatment of subjects suffering from schizophrenia, Alzheimer's disease or other conditions with impaired cognitive function.
    Type: Application
    Filed: March 18, 2008
    Publication date: July 1, 2010
    Inventors: Stacy A. Castner, Thomas Hudzik, Donna L. Maier, Ladislav Mrzljak, Timothy Piser, Jeff S. Smith, Dan Widzowski, Graham Williams
  • Method 741
    Publication number: 20080242688
    Abstract: Methods of treatment and pharmaceutical compositions for providing improved cognition in subjects suffering from schizophrenia, Alzheimer's disease or other conditions with impaired cognitive function.
    Type: Application
    Filed: March 17, 2008
    Publication date: October 2, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Stacy A. Castner, Thomas Hudzik, Donna L. Maier, Ladislav Mrzljak, Timothy Piser, Jeff S. Smith, Dan Widzowski, Graham V. Williams
  • Nicotinic Acetylcholine Receptor Ligands 101
    Publication number: 20080139600
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Application
    Filed: May 17, 2007
    Publication date: June 12, 2008
    Applicant: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Rosuvastatin in pre demented states
    Publication number: 20060229321
    Abstract: Provided is a method of preventing dementia in a patent comprising administering to a patient at risk of developing dementia an effective amount of rosuvastiatin or its pharmaceutically acceptable salt.
    Type: Application
    Filed: October 18, 2002
    Publication date: October 12, 2006
    Inventors: Hans Basun, Timothy Piser, Ihor Rak
  • Estrogen Receptor-beta ligands
    Publication number: 20050043350
    Abstract: A method for treating a disease associated with the estrogen receptor-?, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: Ki?A/Ki?A>25, optionally having general structure (I).
    Type: Application
    Filed: October 10, 2001
    Publication date: February 24, 2005
    Inventors: Bernard Barlaam, James Folmer, Timothy Piser